Key points are not available for this paper at this time.
CAR delivery, aim to improve efficacy and scalability. Integration of artificial intelligence and point-of-care manufacturing may further streamline production and patient selection. Continued innovation will determine the long-term impact of CAR T-cell therapy as a scalable pillar of precision hematologic oncology.
Hernández-Idarraga et al. (Wed,) studied this question.